INNV-12. OUTCOMES IN A REAL-WORLD PRACTICE FOR PATIENTS WITH PRIMARY GLIOBLASTOMA: IMPACT OF A SPECIALIZED NEURO-ONCOLOGY CANCER CARE PROGRAM

Le résumé fourni par la source

Abstract INTRODUCTION Standard care for newly diagnosed glioblastoma consists of maximal surgical resection followed by radiotherapy with concurrent and adjuvant temozolomide. Prognosis for glioblastoma still remains poor, with a reported median survival of 14.6 months. Published data indicate that optimal outcomes in this population require involvement of an experienced team providing multidisciplinary care. We report here the outcomes in a real-world setting for glioblastoma patients treated at a specialized neuro-oncology cancer care program. PATIENTS AND METHODS Data from fifty consecutive patients with primary glioblastoma pursuing care at the Givens Brain tumor Center were analyzed. Coordinated medical care was provided by dedicated neuro-oncology and surgical clinicians, supplemented by care from nurse coordinators, social workers, care guides, genetic counselors, and other specialties. Demographic, pathologic, and clinical information was abstracted from electronic medical records. RESULTS Median patient age was 58 (range, 23–80) years and 26% were ≥65 years of age. Gross total resection was achieved in 91.5% patients, with 56% of resections performed in the Institution’s iMRI suite. A majority of patients received radiation and chemotherapy. In accordance with cancer program guidelines, 48% of the cases were presented at multidisciplinary tumor conferences. A LifeCourse™ care guide was utilized by 30% of the patients. Bevacizumab was used as second-line therapy with/without carboplatin in 63.2% patients. Optune treatment was administered to 27 patients. Additionally, eligible patients enrolled in clinical trials both at primary and recurrent stages. Median progression-free survival (PFS) and overall survival (OS) was 9.1 (range, 2.2–30.5) months and 19.4 (range, 4.6–31.8) months, respectively. End-of-life hospice care was elected by 48% patients. CONCLUSION PFS and OS in this real-world settings were comparable to outcomes noted in controlled clinical trials. These results indicate that efficient, quality care may be achieved with a multidisciplinary treatment approach, producing exceptional survival rates in patients with glioblastoma.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.